Genmab — Maj 2026
-
Lytter pt til cc og mit indtryk er, at der er fuld damp på og selvfølgelig skal der data til for at vi bliver overbeviste om at de opkøbte stoffer har været en god ide. Indfrier data forventingerne så skal vi nok blive belønnet. Men som de også påpeger så er der hård konkurrence på de sygdomme de arbejder med.
-
Whether or not Genmab did right or wrong in disclosing the details of that Peto increase; i still believe in their technological platform and their scientific rigour and i like their disciplined approach and their ruthless cutting of programs that don't meet their standards (as much as it hurts...).
-
At the same time they are massively investing in Peto and Rina-S; given the above I find it very hard to believe they would do this if they had ANY doubt about these programs. It is all about execution, speedy and broad approvals with a clear (and statistically strong) outperformance over other drugs.
-
Too many people around me are developing cancer, all kinds of cancer. Maybe my wish for Genmab to succeed is colored by this, but I believe they are on the right track to help a lot of patients. If science and data prove them right; earnings calls will be a lot easier...
-
Major Shareholder Announcement https://proinvestor.com/investornyt/1442512/major-shareholder-announcement
-
NICE issues Final Draft Guidance recommending that RYBREVANT
▼ (amivantamab) with carboplatin and pemetrexed can be used during a managed access period for untreated advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults https://www.jnj.com/innovativemedicine/uk/media-center/press-releases/nice-guidance-rybrevant-nsclc-egfr-exon20-managed-access -
Denecimig excels at reducing bleeds in hemophilia A patients: Study https://hemophilianewstoday.com/news/denecimig-excels-reducing-bleeds-hemophilia-a-patients/
-
The study of GEN1057 has been terminated due to marginal anti-tumor activity not supporting further development, Ref ClinicalTrials (NCT06573294) 8/5 2026. This was one of the 100% owned Genmab antibodies. The study started 28/8 2024 and stopped after enrolling 23 patients.
-
Genmab får gentaget "køb" hos Jefferies efter frustrationsreaktioner på forskningsnyt https://proinvestor.com/investornyt/1442956/genmab-far-gentaget-kob-hos-jefferies-efter-frustrationsreaktioner-pa-forskningsnyt
-
Stockwatch DK
@StockwatchDK
$GMAB
UBS reiterates its Buy rating on Genmab with a price target of DKK 2,600, saying the Q1 results were broadly in line with expectations. https://x.com/StockwatchDK/status/2053765010724159767
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind